Mongolia approves Russia’s Sputnik V vaccine against COVID-19Society
On February 9, the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the Ministry of Health of Mongolia.
The vaccine was approved under the emergency use authorization procedure without additional clinical trials in the country. The EUA was obtained with the assistance from RDIF's local partner Mongol Emimpex Concern LLC, the country's leading pharmaceutical company.
Mongolia has become the 23rd country in the world to approve Sputnik V. The vaccine had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar and Pakistan.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund said “Partners in Mongolia decided to authorize the vaccine after conducting a thorough review of the data of Sputnik V clinical trial demonstrating its high efficacy and safety as confirmed by the publication in The Lancet magazine. Sputnik V is one of the leading vaccines in the world and the number of registrations of the vaccine keeps growing day by day.”
Sputnik V has a number of key advantages:
- Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals; it is one of only three vaccines in the world with efficacy of over 90%; Sputnik V provides full protection against severe cases of COVID-19.
- The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
- Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
- The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
- The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.
- There are no strong allergies caused by Sputnik V.
- The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
- The price of Sputnik V is less than $10 per shot, making it affordable around the world.
source: Russian Direct Investment Fund